Pfizer Keeps IPR Winning Streak; Court Affirms Ruling On Tygacil Patent
Executive Summary
Federal Circuit finds Patent Trial and Appeal Board was correct in deciding composition patent on antibiotic was not obvious; Pfizer's inter partes review petition challenging Alzheimer's-related patent ended in settlement.